Dexcom beats Street in Q4 on 13% sales growth

2026-02-27 08:28:24

Dexcom reported strong fourth-quarter results, surpassing analyst expectations with profits of $267.3 million and sales of $1.259 billion, marking a 13% increase. Key highlights include the launch of the Dexcom G7 15 Day CGM and FDA clearance for its smart CGM-integrated basal dosing optimizer. Following the announcement, Dexcom’s shares saw a 1% rise in post-market trading.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.